Olutasidenib

Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.^[1][2] Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor.^[1] It is taken by mouth.^[1]

Olutasidenib

Clinical data
Trade names	Rezlidhia
Other names	FT-2102
License data	US DailyMed: Olutasidenib
Routes of administration	By mouth
ATC code	L01XM03 (WHO)
Legal status
Legal status	US: ℞-only[1][2]
Identifiers
CAS Number	1887014-12-1
PubChem CID	118955396
IUPHAR/BPS	10319
DrugBank	DB16267
ChemSpider	72380144
UNII	0T4IMT8S5Z
KEGG	D12483
ChEMBL	ChEMBL4297610
PDB ligand	PWV (PDBe, RCSB PDB)
Chemical and physical data
Formula	C18H15ClN4O2
Molar mass	354.79 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2
InChI InChI=InChI=1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1 Key:NEQYWYXGTJDAKR-JTQLQIEISA-N

The most common adverse reactions include nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis.^[3]

Olutasidenib was approved for medical use in the United States in December 2022,^{[1][2][3][4][5][6]} based on the phase 1 results of a phase 1/2 trial.^[7]

Medical uses

Olutasidenib is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.^[1][2][3]

Society and culture

Names

Olutasidenib is the international nonproprietary name.^[8]